RxDoctor Payments Data

Milledge Newton, MD

Pulmonary Disease · Valdosta, GANPI 1255369435

Payments from drug & device makers

$5,317in general payments, 2019–2025

Across 246 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$846
  • Regeneron Healthcare Solutions, Inc.$785
  • Sanofi$399
  • Sunovion Pharmaceuticals Inc.$266
  • Grifols USA, LLC$202
  • plus $699 from 14 others

What the payments were for

  • Consulting fees$52510%
  • Food & beverage$4,71289%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,317 in reported general payments places this provider in the 50th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$144,687
Medicare patients
485
Services billed
1,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol703$570,173
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$94,390
Dupixent PenDupilumab24$89,639
Stiolto RespimatTiotropium Br/Olodaterol Hcl156$88,844
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr98$60,834
SymbicortBudesonide/Formoterol Fumarate158$48,512
Bevespi AerosphereGlycopyrrolate/Formoterol Fum78$46,761
Spiriva RespimatTiotropium Bromide75$45,382
Albuterol Sulfate HfaAlbuterol Sulfate881$24,640
Breo ElliptaFluticasone/Vilanterol43$17,709
Ventolin HfaAlbuterol Sulfate165$12,736
Advair HfaFluticasone Propion/Salmeterol14$6,975
Fluticasone-SalmeterolFluticasone Propion/Salmeterol55$6,429
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$5,540
Prednisone472$2,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$2,120$665,446939 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$21$172,933240 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$846$134,226231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →